Renal effects of molecular targeted therapies in oncology: A review by the Cancer and the Kidney International Network (C-KIN)

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1677-1684

  Launay Vacher, Vincent ^a,b   Aapro, M ^a,c   De Castro, G ^a,d   Cohen, E ^a,e   Deray, G ^a,b   Dooley, M ^a,f   Humphreys, B ^a,g   Lichtman, S ^a,h   Rey, J ^a,i   Scotte F ^a,j   Wildiers, H ^a,k   Sprangers, B ^a,k  

^a Cancer and the Kidney International Network (C KIN)   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d Sao Paulo State Institute of Cancer   (Brazil)

^e Zablocki Veteran Affairs Medical Center   (United States)

^f MONASH UNIVERSITY   (Australia)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ Jean Godinot Cancer Institute   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Cancer; Kidney disease; Molecular targeted therapy; Nephrotoxicity; Renal failure; Renal toxicity

Indexed keywords

AFATINIB; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DABRAFENIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; LAPATINIB; MONOCLONAL ANTIBODY; NINTEDANIB; PANITUMUMAB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC THERAPY; ANURIA; BELGIUM; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CARDIORENAL SYNDROME; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; DEHYDRATION; DIALYSIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DIMERIZATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DYSURIA; EARLY DIAGNOSIS; ELECTROLYTE DISTURBANCE; FEVER; GLOMERULUS FILTRATION RATE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATURIA; HUMAN; HYPERCALCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; JAPAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY CYST; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY METASTASIS; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEPHRECTOMY; NEPHRITIS; NEPHROLITHIASIS; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; POLLAKISURIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; RENOVASCULAR HYPERTENSION; REVIEW; STOMACH CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; VOMITING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY DISEASES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RANK LIGAND; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84941630151     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv136     Document Type: Review

References (70)

1. Launay-Vacher V, Oudard S, Janus N et al. Renal insufficiency and cancer medications (IRMA) study group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
2. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30: 548-556.
3. Levey AS, Eckardt KU, Tsukamoto Y et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011; 80: 17-28.
4. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735-740.
5. Janus N, Launay-Vacher V, Byloos E et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103: 1815-1821.
6. Canter D, Kutikov A, Sirohi M et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology 2011; 77: 781-785.
7. Nakamura Y, Tsuchiya K, Nitta K, Ando M. Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi 2011; 53: 38-45.
8. Wong G, Hayen A, Chapman JR et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009; 20: 1341-1350.
9. Orskov B, Sørensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2012; 27: 1607-1613.
10. Lowrance WT, Ordoñez J, Udaltsova N et al. CKD and the risk of incident cancer. J Am Soc Nephrol 2014; 25: 2327-2334.
11. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999; 354: 93-99.
12. Engels EA, Pfeiffer RM, Fraumeni JF, Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901.
13. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
14. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009; 20: 81-82.
15. Launay-Vacher V, Janus N, Selle F et al. Results of the MARS study on the management of antiangiogenics' renovascular safety in ovarian cancer. American Society of Clinical Oncology Annual Meeting. J Clin Oncol 2013; 31(suppl): abstr 5567.
16. Goldwasser F, Janus N, Morere JF et al. Results of the MARS study on the management of antiangiogenics' renovascular safety in lung cancer. European Cancer Congress, Eur J Cancer 2013; 49(suppl 2): S819 (abstr 3471).
17. Gligorov J, Janus N, Daniel C et al. Results of the MARS study on the management of antiangiogenics' renovascular safety in breast cancer. Cancer Res 2013; 73(24 Suppl): P3-15.
18. Janus N, Ray-Coquard I, Beuzeboc P et al. Evolution of renal function under antiangiogenic therapy. Results of the MARS study. Nephrol Ther 2013; 9: 353.
19. Launay-Vacher V, Ayllon J, Janus N et al. Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 2011; 29: 492-494.
20. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008; 358: 95-97.
21. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 2009; 15: 5947-5949.
22. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
23. Thariat J, Launay-Vacher V, Italiano A et al. Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer. NDT Plus 2008; 3: 196-197.
24. Thariat J, Azzopardi N, Peyrade F et al. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J Clin Oncol 2008; 26: 4223-4225.
25. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003-3015.
26. Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14: 697-710.
27. Dimke H, van der Wijst J, Alexander TR et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol 2010; 21: 1309-1316.
28. Muallem S, Moe OW. When EGF is offside, magnesium is wasted. J Clin Invest 2007; 117: 2086-2089.
29. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
30. Bou Matar RN, Klein JD, Sands JM. Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats. PLoS One 2013; 8: e54738.
31. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006; 33(Suppl 15): S15-S21.
32. Untch M, Muscholl M, Tjulandin S et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide and epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-1480.
33. Russo G, Cioffi G, Di Lenarda A et al. Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 2012; 7: 439-446.
34. SiteGPR®. Guidelines for prescribing in renal disease [online] 2013. http://www.sitegpr.com (25 March 2015, date last accessed).
35. Albini A, Donatelli F, Focaccetti C et al. Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Intern Emerg Med 2012; 7: 399-401.
36. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471.
37. Regnier-Rosencher E, Lazareth H, Gressier L et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br J Dermatol 2013; 169: 934-938.
38. Launay-Vacher V, Zimner-Rapuch S, Poulalhon N et al. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 2014; 120: 2158-2163.
39. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinibassociated complex renal cysts during continuous crizotinib treatment. Oncologist 2014; 19: 1008-1010.
40. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
41. Seto T, Kiura K, Nishio M et al. CH5424802 (RO5424802) for patients with ALKrearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14: 590-598.
42. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
43. Gastaud L, Ambrosetti D, Otto J et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 2013; 82: 362-364.
44. Shen H, Yang Z, Zhao W et al. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab Dispos 2013; 41: 2095-2103.
45. Leboulleux S, Bastholt L, Krause T et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905.
46. Wells SA, Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141.
47. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
48. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
49. Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2014; 2: 15-18.
50. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 34-44.
51. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
52. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
53. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
54. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
55. Lipton A, Siena S, Rader M et al. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Ann Oncol 2010; 21: 380.
56. Klejna K, Naumnik B, Gasowska K, Myśliwiec M. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 2009; 47: 199-206.
57. Raggi P, Giachelli C, Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007; 4: 26-33.
58. Kartsogiannis V, Zhou H, Horwood NJ et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999; 25: 525-534.
59. Hainsworth JD, Waterhouse DM, Penley WC et al. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI oncology research consortium. Cancer Invest 2013; 31: 323-329.
60. van den Eertwegh AJ, Karakiewicz P, Bavbek S et al. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology 2013; 81: 143-149.
61. Koh Y, Lim HY, Ahn JH et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24: 1026-1031.
62. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
63. Amato RJ, Jac J, Giessinger S et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438-2446.
64. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
65. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
66. Izzedine H, Boostandoot E, Spano JP et al. Temsirolimus-induced glomerulopathy. Oncology 2009; 76: 170-172.
67. Javle MM, Shroff RT, Xiong H et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010; 10: 368.
68. Launay-Vacher V, Storme T, Izzedine H, Deray G. Pharmacokinetic changes in renal failure. Presse Med 2001; 30: 597-604.
69. Lichtman SM, Wildiers H, Launay-Vacher V et al. International society of geriatric oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43: 14-34.
70. Aronoff GR, Brier ME. Drug Prescribing in Renal Failure. 5th edition. Philadelphia, PA: American College of Physicians, 2007.